Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-center, Open, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of MG4101 in Hepatocellular Carcinoma After TACE

NCT02854839 is registered in ClinicalTrials.gov with GC Cell Corporation as lead sponsor.

NCT NCT02854839
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02854839 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-center, Open, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of MG4101 in Hepatocellular Carcinoma After TACE
Lead sponsor
GC Cell Corporation
Phase
Phase 2
Overall status
Completed
Start date
November 28, 2016
Completion date
September 17, 2019
Enrollment
78 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma